January 7, 2025 03:15 PM EST
FDA+

Af­ter a bump in ad­comms in 2023, FDA ad­vi­so­ry pan­els re­turned to 2022 lev­els

Max Bayer

Pharma Reporter

The FDA held 13 ad­vi­so­ry com­mit­tee pan­els last year to dis­cuss spe­cif­ic prod­uct ap­pli­ca­tions, half the to­tal in 2023 and com­pared with nine in 2022 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Gene edit­ing start­up Scribe Ther­a­peu­tics lets go of staff as it preps for the clin­ic

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

FDA of­fers suite of new guid­ance on AI, ac­cel­er­at­ed ap­provals, clin­i­cal tri­als and more

A service from the Financial Times